Tags: Chemical Compound, Chemical Substance.

Orteronel (TAK-700) is an experimental drug for the treatment of cancer discovered by Takeda Pharmaceutical Company and under development by Millennium Pharmaceuticals. It is currently in Phase III clinical trials for metastatic hormone-refractory prostate cancer.Orteronel is an androgen synthesis inhibitor. It selectively inhibits the enzyme CYP17A1 which is expressed in testicular adrenal and prostatic tumor tissues.

Orteronel.svg
IUPAC name
6-(7-Hydroxy-67-dihydro-5H-pyrrolo[12-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide

Loading...

This page contains content from the copyrighted Wikipedia article "Orteronel"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.